Egyszerű keresés   |   Összetett keresés   |   Böngészés   |   Kosár   |   Súgó  


Részletek

A cikk állandó MOB linkje:
http://mob.gyemszi.hu/detailsperm.jsp?PERMID=149953
MOB:2021/2
Szerzők:Áy Éva; Pocskay Ágnes; Lakatos Botond; Szlávik János; Mezei Mária; Minárovits János
Tárgyszavak:HIV; GYÓGYSZER-REZISZTENCIA ; MAGYARORSZÁG
Folyóirat:Acta Microbiologica et Immunologica Hungarica - 2021. 68. évf. 2. sz.
[https://akjournals.com/view/journals/030/030-overview.xml]


  Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Hungary / Éva Áy [et al.]
  Bibliogr.: p. 90-91. - Abstr. eng. - DOI: https://doi.org/10.1556/030.2021.01433
  In: Acta Microbiologica et Immunologica Hungarica. - ISSN 1217-8950. - 2021. 68. évf. 2. sz., p. 87-91. : ill.


Widespread introduction of HIV integrase inhibitors into clinical care may result in appearance of drug resistance mutations affecting treatment outcome. The aim of our study was to monitor the resistance patterns of integrase inhibitors beside protease and reverse transcriptase inhibitors in newly diagnosed therapy-naive HIV-positive patients in Hungary between 2017 and 2019. Genotype-based resistance testing of HIV integrase, protease and reverse transcriptase was performed by amplification and Sanger population sequencing from plasma samples. Drug resistance mutations were identified by the algorithm of Stanford HIV Drug Resistance Database. Potentially transmitted, non-polymorphic integrase major mutation was detected in 1 out of 249 samples, while accessory mutations were observed in further 31 patients (12.4%). The overall prevalence of transmitted drug resistance (TDR) mutations related to protease and reverse transcriptase inhibitors was 5.8% (10/173) between the end of 2017 and 2019. Nucleoside reverse transcriptase inhibitor associated resistance mutations were the most frequent indicators of TDR (6/173; 3.5%), followed by resistance mutations associated with protease (3/173; 1.7%) and non-nucleoside reverse transcriptase inhibitors (2/173, 1.2%). The first detection of integrase major mutation and the changing patterns of other resistance mutations in Hungarian untreated HIV-positive population indicate the necessity of continuous molecular surveillance of Hungarian HIV epidemic.  Kulcsszavak: integrase resistance mutations, Hungary, transmitted drug resistance